PharmaRoth Labs (PharmaRoth Labs) Debt-to-Asset : 0.00 (As of Mar. 2011)

View and export this data going back to 2008. Start your Free Trial

What is PharmaRoth Labs Debt-to-Asset?

PharmaRoth Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2011 was $0.00 Mil. PharmaRoth Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2011 was $0.00 Mil. PharmaRoth Labs's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2011 was $0.10 Mil. PharmaRoth Labs's debt to asset for the quarter that ended in Mar. 2011 was 0.00.

PharmaRoth Labs Debt-to-Asset Historical Data

The historical data trend for PharmaRoth Labs's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaRoth Labs Debt-to-Asset Chart

PharmaRoth Labs Annual Data

Trend

Jun08

Jun09

Jun10

Debt-to-Asset

PharmaRoth Labs Quarterly Data
	Mar07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11
Debt-to-Asset	Get a 7-Day Free Trial											-	-	-	8.93	-

Competitive Comparison of PharmaRoth Labs's Debt-to-Asset

For the Biotechnology subindustry, PharmaRoth Labs's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaRoth Labs's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaRoth Labs's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where PharmaRoth Labs's Debt-to-Asset falls into.

PharmaRoth Labs Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

PharmaRoth Labs's Debt-to-Asset for the fiscal year that ended in Jun. 2010 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0.25)	/	0
	=	N/A

PharmaRoth Labs's Debt-to-Asset for the quarter that ended in Mar. 2011 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	0.095
	=	0.00

PharmaRoth Labs (GREY:ROTH) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

PharmaRoth Labs Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of PharmaRoth Labs's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaRoth Labs (PharmaRoth Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaRoth Labs Inc (GREY:ROTH) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

8250 West Charleston Boulevard, Suite 110, Las Vegas, NV, USA, 89117

Website

http://www.pharmaroth.com

PharmaRoth Labs Inc is engaged in the manufacture and sale of a treatment for Type II diabetes called Sucanon. The company also does marketing and selling of nutraceutical drugs.

PharmaRoth Labs (PharmaRoth Labs) Headlines

From GuruFocus

Hotchkis and Wiley Value Opportunities Fund Buys Rothschild SCA, Oracle Corp, Medtronic PLC, Sells Amerco Inc, Anthem Inc, F5 Inc

By GuruFocusNews insider • 03-29-2022